RxDoctor Payments Data

Randy Grellner, DO

Family Medicine · Cushing, OKNPI 1356364376

Payments from drug & device makers

$8,212in general payments, 2019–2025

Across 533 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$1K
  • GSK$825
  • Lilly USA, LLC$501
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$430
  • Novo Nordisk$368
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,200100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,212 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$257,014
Medicare patients
600
Services billed
39,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide98$102,082
EliquisApixaban108$98,807
OzempicSemaglutide78$87,529
TrulicityDulaglutide63$68,081
FarxigaDapagliflozin Propanediol67$49,687
JardianceEmpagliflozin67$49,026
XareltoRivaroxaban36$46,770
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$42,838
JanuviaSitagliptin Phosphate49$35,804
GlyxambiEmpagliflozin/Linagliptin48$34,060
JanumetSitagliptin Phos/Metformin Hcl30$31,603
MyrbetriqMirabegron45$24,231
RybelsusSemaglutide17$21,505
InvokanaCanagliflozin14$19,411
Soliqua 100-33Insulin Glargine/Lixisenatide22$19,205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$501$170,163161 claims
Novo NordiskOzempic, Rybelsus$368$109,03495 claims
PfizerEliquis, Premarin$322$104,630129 claims
Boehringer IngelheimJardiance, Glyxambi, Combivent Respimat, Synjardy$198$97,861138 claims
MerckJanuvia, Janumet, Janumet Xr, Steglatro$198$79,405107 claims
Johnson & JohnsonXarelto, Invokana$229$66,18050 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,280$59,48983 claims
GSKTrelegy Ellipta$825$42,83865 claims
Astellas Pharma US IncMyrbetriq$60$24,23145 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$184$19,20522 claims
Sumitomo Pharma America, Inc.Gemtesa$127$13,94825 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$95$6,90213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Cushing

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →